Policy liaison initiative: Relevant and accessible evidence from The Cochrane Library
Logo for Australasian Cochrane Centre
Arthritis & Musculoskeletal Asthma Cancer Cardiovascular Diabetes Injury Mental Health

Policy liaison home
Review summaries
Cochrane & Cancer
Topics & Reviews
Review summaries
Australia's contribution 
Impact on health care
Research priorities

Other policy relevant Cochrane work 
Effective Practice and Organisation of Care
Consumers and Communication 
Evidence-Based Policy Network 
About the EBPN
Events
Bulletin - latest news
Helpdesk for EBPN
Res
ources 
Cochrane Library logon
NICS Cochrane Library guide
Australasian Cochrane Centre
National Health Priority Areas website

Cancer reviews by topic

Issue 7, 2010 of The Cochrane Library included 6 reviews and 6 protocols on the prevention, screening and treatment of National Health Priority Cancers.  Topics and reviews on priority cancers can be viewed below.

Click on the title to view the full review or protocol

Log on to The Cochrane Library to read protocols and full reviews. (click here for search tip)

[R] Cochrane review

[P] Protocol for Cochrane review
[S] Summary of Cochrane review available

 

 Quick links to topics on this page:

 

Other health priority cancer topics available on this site:

 
Topic Reviews and Protocols 
Click on title to view review or protocol
Supportive care for cancer patients
  1. Exercise interventions on health related quality of life for cancer survivors  [P]
  2. Exercise interventions on health related quality of life for people with cancer during active treatment  [P]
  3. Interventions to enhance return-to-work for cancer patients  [P]
  4. Interventions to improve continuity of care in the follow-up of patients with cancer  [P]
  5. Multidimensional rehabilitation programmes for adult cancer survivors  [P]
  6. Nutritional support in children and young people with cancer undergoing chemotherapy  [R]
  7. Recordings or summaries of consultations for people with cancer  [R]
  8. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer  [R]

Back to Top

Psychological interventions
  1. Communication skills training for health care professionals working with cancer patients, their families and/or carers  [R] [S]
  2. Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients  [P]

Back to Top

Pain management Psychological therapies
  1. No reviews currently available for this topic

Back to Top

Pharmacological therapies
  1. Anticonvulsant drugs for acute and chronic pain  [R]
  2. Antipsychotics for acute and chronic pain in adults  [R]
  3. Bisphosphonates for the relief of pain secondary to bone metastases  [R]
  4. Buprenorphine for cancer pain  [P]
  5. Calcitonin for metastatic bone pain  [R] [s]
  6. Celiac plexus block for pancreatic cancer pain in adults  [P]
  7. Chemotherapy and/or radiotherapy after surgery for ovarian carcinosarcoma  [P]
  8. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma  [R]
  9. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction  [R]
  10. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer  [R]  [S]
  11. Fentanyl for chronic pain  [P]
  12. Hydromorphone for acute and chronic pain  [R]
  13. Ketamine as an adjuvant to opioids for cancer pain  [R] [s]
  14. Lamotrigine for acute and chronic pain  [R]
  15. Methadone for cancer pain  [R]
  16. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain  [R]  [S]
  17. Opioids for the management of episodic pain in cancer patients  [R]  [S]
  18. Opioid switching to improve pain relief and drug tolerability  [R]  [S]
  19. Oral morphine for cancer pain  [R]  [s]
  20. Oxycodone for cancer-related pain  [P]
  21. Single dose oral etodolac for acute postoperative pain in adults  [R]
  22. Single dose oral flurbiprofen for acute postoperative pain in adults  [R]

Back to Top

Invasive therapies
  1. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer  [R]  [S]
  2. Pleurodesis for malignant pleural effusions  [R] [s]

Back to Top

Physical therapies
  1. Exercise for treatment of cancer related fatigue  [P]
  2. Transcutaneous Electric Nerve Stimulation (TENS) for cancer pain in adults  [R]

Back to Top

Radiotherapy and radioisotopes
  1. Radiotherapy for the palliation of painful bone metastases  [R]
  2. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases  [R]

Back to Top

  1. Radioisotopes for metastatic bone pain  [R]  [s]

Back to Top

Complementary therapies
  1. Acupuncture for cancer pain in adults  [P]
  2. Aromatherapy and massage for symptom relief in patients with cance[R] [s]
  3. Dance movement therapy for improving psychological and physical outcomes in cancer patients  [P]
  4. Ganoderma Lucidum (Reishi mushroom) for cancer treatment  [P]
  5. Green tea (Camellia sinensis) for the prevention of cancer  [R]
  6. Hyperbaric oxygenation for tumour sensitisation to radiotherapy  [R]
  7. Laetrile treatment for cance[R]  [S]
  8. Mistletoe therapy in oncology  [R]
  9. Music for pain relief  [R]  [S]
  10. Music interventions for improving psychological and physical outcomes in cancer patients  [P]
  11. Selenium for preventing cancer  [P]
  12. Thymus extracts for cancer  [P]
  13. Vitamin D supplementation for prevention of cancer in adults  [P]

Back to Top

Treatments for side effects of cancer treatment  
  1. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients  [R]  [S]

  2. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia  [R]
  3. Amphotericin B versus fluconazole for controlling fungal infections in cancer patients with neutropenia  [R]
  4. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy  [R]

  5. Antibiotics plus colony stimulating factors (CSFs) versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation  [P]
  6. Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation  [P]
  7. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer  [R]
  8. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer  [R]
  9. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood  [P]
  10. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases  [R]

  11. Anti-pseudomonal beta-lactam monotherapy for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams  [P]

  12. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors  [P]

  13. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults  [R]
  14. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia  [R]  [s]
  15. Cardioprotective interventions for patients receiving anthracyclines  [R]  [S]
  16. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients  [R]  [S]

  17. Colony stimulating factors for chemotherapy induced febrile neutropenia  [R]  [s]
  18. Different anthracycline derivates for reducing cardiotoxicity in cancer patients  [R]  [S]

  19. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy  [R]  [S]

  20. Droperidol for treatment of nausea and vomiting in palliative care patients  [P]

  21. Drug therapy for the management of cancer-related fatigue  [R]

  22. Educational interventions for the management of cancer-related fatigue in adults  [P]
  23. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data  [R]

  24. Exercise for the management of cancer-related fatigue in adults  [R]

  25. Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity  [P]

  26. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction  [R]

  27. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction  [R]  [S]

  28. Haloperidol for treatment of nausea and vomiting in palliative care patients  [R]

  29. Hepatic late adverse effects after treatment for childhood cancer  [P]
  30. Homeopathic medicines for adverse effects of cancer treatments  [R]
  31. Hyperbaric oxygen therapy for late radiation tissue injury  [R]

  32. Influenza vaccination in children being treated with chemotherapy for cancer  [R]
  33. Interventions for cough in malignant disease  [P]
  34. Interventions for preventing and managing radiation-induced skin reactions in cancer patients  [P]
  35. Interventions for preventing oral candidiasis for patients with cancer receiving treatment  [R]
  36. Interventions for preventing oral mucositis for patients with cancer receiving treatment  [R]  [s]
  37. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy  [P]
  38. Interventions for sexual dysfunction following treatments for cancer  [R]

  39. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer  [R]

  40. Interventions for treating oral candidiasis for patients with cancer receiving treatment  [R]  [S]
  41. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter related infections in children with cancer  [P]
  42. Low bacterial diet to prevent infection in neutropenic patients  [P]

  43. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer  [P]
  44. Medically assisted hydration for palliative care patients  [R]

  45. Metoclopramide for chronic nausea in adult palliative care patients with advanced cancer  [P]
  46. Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting  [P]

  47. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases  [R]

  48. Nystatin prophylaxis and treatment in severely immunodepressed patients  [R]
  49. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients  [R]  [S] 
  50. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy  [R]
  51. Physical therapies for reducing and controlling lymphoedema of the limbs  [R]  [S]
  52. Pneumococcal vaccines for prevention of Streptococcus pneumoniae disease in patients undergoing chemotherapy and/or radiotherapy  [P]
  53. Pre and peri-operative erythropoeitin for reducing allogeneic blood transfusions in colorectal cancer surgery  [R]

  54. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection  [R]

  55. Prevention and treatment interventions for nausea and vomiting during initiation of chronic opioid therapy  [P]

  56. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy  [P]

  57. Prophylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy  [R]

  58. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients  [R]
  59. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation  [R]  [S]
  60. Psychosocial interventions for reducing fatigue during cancer treatment in adults  [R] 

  61. Routine versus selective antifungal administration for control of fungal infection in patients with cance[R]
  62. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients  [R]  [S]

  63. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults  [P]

  64. Topical agents and dressings for fungating wounds  [R]
  65. Urate oxidase for prevention and treatment of tumor lysis syndrome in children with cancer  [R]

  66. Voriconazole versus amphotericin B and fluconazole in cancer patients with neutropenia  [R]

Back to Top

Other Cancer Reviews   Ear nose and throat cancers
  1. Angiogenesis-inhibitors for metastatic thyroid cancer  [R]

  2. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma  [R]

  3. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer  [P]

  4. Perioperative prophylactic antibiotics in head and neck cancer surgery  [P]

  5. Preoperative chemotherapy for resectable thoracic esophageal cancer  [R]

  6. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer  [R]

Gynaecological Cancers
  1. Adjuvant chemotherapy and/or radiotherapy after surgery for uterine carcinosarcoma  [P]

  2. Adjuvant chemotherapy for endometrial cancer  [P]

  3. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer  [R]

  4. Adjuvant radiotherapy for Stage I endometrial cancer  [P]

  5. Antigen-specific active immunotherapy for ovarian cancer  [P]

  6. Anti-inflammatory agents for preventing the progression of cervical intraepithelial neoplasia  [P]

  7. Barrier agents for adhesion prevention after gynaecological surgery  [R]

  8. Chemotherapy and/or radiotherapy after surgery for ovarian carcinosarcoma  [R]

  9. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma  [R]

  10. Chemotherapy for malignant germ cell ovarian cancer in patients with early stage, advanced and recurrent disease  [P]

  11. Chemotherapy for relapsed epithelial ovarian cancer  [P]

  12. Combination chemotherapy for high-risk gestational trophoblastic tumour  [R]

  13. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer  [R]

  14. DNA-repair pathway inhibitors for the treatment of ovarian cancer  [R]

  15. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment  [P]

  16. First line chemotherapy in low risk gestational trophoblastic neoplasia  [R]

  17. Interval debulking surgery for advanced epithelial ovarian cancer  [R]

  18. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy  [R]

  19. Interventions for the treatment of borderline ovarian tumours  [P]

  20. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer  [R]

  21. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer  [R]

  22. Lymphadenectomy for the management of endometrial cancer  [P]

  23. Maintenance chemotherapy for ovarian cancer  [P]

  24. Management of drainage for malignant ascites in gynaecological cancer  [P]

  25. Neoadjuvant chemoradiation for advanced primary vulvar cancer  [R]  [S]

  26. Optimal primary surgical treatment for advanced epithelial ovarian cancer  [P]

  27. Palliative surgery versus medical management for bowel obstruction in ovarian cancer  [R]

  28. Pegylated liposomal doxorubicin for relapsed ovarian cancer  [P]

  29. Perioperative enhanced recovery programmes for gynaecological cancer patients  [R]

  30. Primary groin irradiation vs primary groin surgery for early vulvar cancer  [R]

  31. Progestagens for endometrial cancer  [R]

  32. Prophylactic chemotherapy for hydatidiform mole  [P]

  33. Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies  [P]

  34. Surgical interventions for early squamous cell carcinoma of the vulva  [R]

  35. Topotecan for ovarian cancer  [R]

  36. Ultraradical surgery for the primary debulking of epithelial ovarian cancer  [P]

Haematological Malignancies

  1. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk  [R]

  2. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia  [R]

  3. First-line double high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma  [P]

  4. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma  [R]

  5. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation  [R]

  6. Interventions for early stage Hodgkin's disease in children  [R]

  7. Purine Antagonists for Chronic Lymphocytic Leukaemia  [R]

Hepato-biliary Cancers

  1. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B  [R]  [S]

  2. Antioxidant supplements for preventing gastrointestinal cancers  [R]

  3. Cryotherapy for hepatocellular carcinoma  [P]

  4. Interferon for hepatocellular carcinoma  [P]

  5. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases  [R]

  6. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma  [R]

  7. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma  [R]

  8. Surgical resection for hepatocellular carcinoma  [P]

  9. Systemic chemotherapy for inoperable hepatocellular carcinoma  [P]

  10. Tamoxifen for hepatocellular carcinoma  [R]

  11. Transcatheter arterial embolisation and chemoembolisation for hepatocellular carcinoma  [P]

Oral Cancer

  1. Interventions for the treatment of oral cancer  [P]

  2. Screening programmes for the early detection and prevention of oral cancer  [R]  [S]

  3. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus  [R]

Renal Cancers

  1. Adjuvant chemotherapy for invasive bladder cancer (individual patient data)  [R]

  2. High dose versus low dose intravesical interferon-alpha 2b for the treatment of carcinoma in situ of the bladder  [P]

  3. Immunotherapy for advanced renal cell cancer  [R]

  4. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer  [R]  [S]

  5. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer  [P]

  6. Laparoscopic radical cystectomy for bladder cancer  [P]

  7. Neoadjuvant chemotherapy for invasive bladder cancer  [R]  [S]

  8. Neoadjuvant cisplatin for advanced bladder cancer  [R]

  9. Surgery versus radiotherapy for muscle invasive bladder cancer  [R]

  10. Targeted therapy for advanced renal cell carcinoma  [R]

Back to Top

Last updated 19 Jul 2010

This website is produced and maintained  by the Australasian Cochrane Centre for members of the Evidence-Based Policy Network, Australian Government Department of Health and Ageing.